

Dated: October 21, 2019.

Melanie J. Pantoja,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2019-23285 Filed 10-24-19; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed).

Date: November 4–6, 2019.

Time: 9:00 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 5601 Fishers Lane, Rockville, MD 20892 (Virtual Meeting).

Contact Person: Ellen S. Buczko, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, Room #3F30A, National Institutes of Health/ NIAID, 5601 Fishers Lane, MSC 9824, Bethesda, MD 20892-9824, (240) 669-5028, ebuczko1@niaid.nih.gov.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: October 21, 2019.

Tyeshia M. Roberson,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2019-23281 Filed 10-24-19; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Aging; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute on Aging Special Emphasis Panel; SWAN.

Date: November 18, 2019.

Time: 11:00 a.m. to 1:30 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institute on Aging, Gateway Building, 7201 Wisconsin Avenue, Bethesda, MD 20892 (Telephone Conference Call).

Contact Person: Isis S. Mikhail, MD, MPH, DrPH, Scientific Review Officer, Scientific Review Branch, National Institute on Aging, National Institutes of Health, Gateway Building 2C212, 7201 Wisconsin Avenue, Bethesda, MD 20892, Tel: 301-402-7704, mikhaili@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging Research, National Institutes of Health, HHS)

Dated: October 21, 2019.

Melanie J. Pantoja,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2019-23290 Filed 10-24-19; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Submission for OMB Review; 30-Day Comment Request; Summer Research Internship Program (National Institute on Drug Abuse)

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: In compliance with the Paperwork Reduction Act of 1995, the National Institutes of Health (NIH) has submitted to the Office of Management

and Budget (OMB) a request for review and approval of the information collection listed below.

DATES: Comments regarding this information collection are best assured of having their full effect if received within 30 days of the date of this publication.

ADDRESSES: Written comments and/or suggestions regarding the item(s) contained in this notice, especially regarding the estimated public burden and associated response time, should be directed to the: Office of Management and Budget, Office of Regulatory Affairs, OIRA_submission@omb.eop.gov or by fax to 202-395-6974, Attention: Desk Officer for NIH.

FOR FURTHER INFORMATION CONTACT: To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact: Dr. Albert Avila, Director, National Institute on Drug Abuse, Office of Diversity and Health Disparity, Neuroscience Center, Building 6001, Room 3106, Rockville, Maryland 20852 or call non-toll-free number (301) 496-8804 or Email your request, including your address, to: aavila@nida.nih.gov. Formal requests for additional plans and instruments must be requested in writing.

SUPPLEMENTARY INFORMATION: This proposed information collection was previously published in the **Federal Register** on March 12, 2019, page 8881 (84 FR 8881) and allowed 60 days for public comment. No public comments were received. The purpose of this notice is to allow an additional 30 days for public comment. The National Institute on Drug Abuse (NIDA), National Institutes of Health, may not conduct or sponsor, and the respondent is not required to respond to, an information collection that has been extended, revised, or implemented on or after October 1, 1995, unless it displays a currently valid OMB control number.

In compliance with Section 3507(a)(1)(D) of the Paperwork Reduction Act of 1995, the National Institutes of Health (NIH) has submitted to the Office of Management and Budget (OMB) a request for review and approval of the information collection listed below.

Proposed Collection Title: NIDA Summer Research Internship Program, 0925-0738, Expiration 03/31/2019, REINSTATEMENT WITH CHANGE, National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH).

Need and Use of Information Collection: The purpose of the proposed information is for the selection of

interns for the continuing NIDA Summer Research Internship Program. This request is to allow NIDA to collect information from applicants in order to meet the goals of the program and IC mission. Applicant eligibility for this program was 17 years, but is now open to those 18 and over in the year of application per NIH policy document 2019 High School Summer Internship Program (HS-SIP) Policy. NIDA will

request clearance for any additional forms should new programs be introduced in the future. The information ensures that students applying to this program meet basic eligibility requirements; indicates their interest in substance abuse research, future career goals, and, if selected for the program, what research they prefer to conduct. The information also enables decision-making regarding

which applicants will be selected for internships. In each case, completing the application is voluntary, but in order to receive due consideration, the prospective applicant must complete all fields required by the program.

OMB approval is requested for 3 years. There are no costs to respondents other than their time. The total estimated annualized burden hours are 250.

ESTIMATED ANNUALIZED BURDEN HOURS

Form	Type of respondent	Number of respondents	Number of responses per respondent	Average burden per response (in hours)	Estimated total annual burden hours
Summer Internship	Individuals-household	250	1	1	250
Total	250	250

Dated: October 16, 2019.

Lanette A. Palmquist,

Project Clearance Liaison, National Institute on Drug Abuse, National Institutes of Health.

[FR Doc. 2019-23283 Filed 10-24-19; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Center for Advancing Translational Sciences; Notice of Workshop

Notice is hereby given of a workshop convened by the National Center for Advancing Translational Sciences Cures Acceleration Network Review Board.

Purpose

The National Center for Advancing Translational Sciences is hosting the Cures Acceleration Network Review Board (CAN RB) Workshop: The CAN RB advises and provides recommendations to the NCATS Director with respect to significant barriers to successful translation of basic science into clinical application. In support of this mandate, the CAN RB will co-host this public workshop to discuss challenges around finding new uses for drugs that are already on the market but lack commercial and regulatory incentives for research and development.

The Workshop is being co-sponsored by the NCATS Cures Acceleration Network Review Board, NCATS Drug Development Partnership Programs, Food and Drug Administration, and Reagan-Udall Foundation for the FDA.

Name of Committee: National Center for Advancing Translational Sciences Cures Acceleration Network Review Board.

Type of Meeting: Repurposing Off-Patent Drugs: Research & Regulatory Challenges.

Date: December 5–6, 2019.

Time: 7:30 a.m. to 5:00 p.m., Eastern Standard Time (EST).

Agenda: The Workshop will assess challenges around finding new uses for drugs that are already on the market but lack commercial and regulatory incentives for research and development. On December 5, we will map out the challenges to repurposing off-patent drugs. On December 6, we will host interactive work sessions focused on capturing possible solutions.

Place: Hilton Washington DC/ Rockville Hotel & Executive Meeting Center, 1750 Rockville Pike, Rockville, MD 20852.

Cost: The meeting is free and open to the public.

Registration: Registration is required. Using the link below, attendees can register by December 2, 2019, 5:00 p.m. EST. Early registration is recommended due to limited seating. <https://reaganudall.salsalabs.org/repurposingoffpatentdrugsworkshop/index.html>.

Access: Twinbrook Metro Station (Red Line).

Contact Person: Bobbie Ann Mount, Ph.D., Program Officer, Drug Development Partnership Programs, Office of the Director, National Center for Advancing Translational Sciences, National Institutes of Health.

Telephone: 301.435.0824, Email:

NewTherapeuticUses@mail.nih.gov.

Disability Accommodations: Individuals whose full participation in

the workshop will require special accommodations (e.g., sign language, or interpreting services, etc.) must submit a request to the Contact Person listed on the notice at least ten (10) business days prior to the meeting. Such requests should include a detailed description of the accommodation needed and a way to contact the requester if more information is needed to fill the request. Special requests should be made as early as possible. Last minute requests may be made but may not be possible to accommodate.

Security: Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver's license, or passport) and to state the purpose of their visit. Also, as a part of security procedures, attendees should be prepared to present a photo ID at the meeting registration desk during the check-in process. Pre-registration is recommended. Seating will be limited to the room capacity and seats will be on a first come, first serve basis, with expedited check-in for those who are pre-registered.

Meeting schedule subject to change.

For more information, visit: <https://reaganudall.salsalabs.org/repurposingoffpatentdrugsworkshop/index.html>.

Dated: October 21, 2019.

Melanie J. Pantoja,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2019-23280 Filed 10-24-19; 8:45 am]

BILLING CODE 4140-01-P